Digestive Disease Week (DDW) 2019

Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis

Correlation of Fecal Calprotectin and C-Reactive Protein Concentrations With Clinical Outcomes and Endoscopic Disease Activity in Patients With Ulcerative Colitis Receiving Induction Therapy With Etrasimod

14th Congress of European Crohn’s and Colitis Organisation (ECCO) 2019

Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis

ASPET at Experimental Biology (EB) 2017

Etrasimod, a Novel Sphingosine-1-Phosphate Receptor (S1PR1) Modulator, Lacks Functional Activity at S1P2 Receptors

Etrasimod (APD334), an Oral, Next-Generation Sphingosine-1-Phosphate Receptor Modulator Inhibits the Development of Colitis in Lymphoid-Null Mice Injected With Colitogenic CD4+ T Cells

Functional Activity of Etrasimod and a Diverse Panel of Sphingosine-1-Phosphate Receptor (S1PR1) Modulators at S1P4 Receptors

Autoimmunity Reviews 16 (2‍0‍1‍7)495-503

Modulation of sphingosine-1-phosphate in inflammatory bowel disease

Advances in Inflammatory Bowel Diseases (AIBD) Meeting 2016

Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral, Selective S1P Receptor Modulator, after Single Dose Escalation in Healthy Volunteers

Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Preclinical Autoimmune Disease-modifying Activity Exhibits Favorable PK/PD Properties in Healthy Volunteers

Preclinical Safety Assessment of Etrasimod (APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator With a Favorable Profile

The Sphingosine-1-Phosphate Receptor (S1P) Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart Rate in Preclinical Testing

1 2

For Medical Information, contact us at medinfo@arenapharm.com